Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects. ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyt ...
Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...
We are thrilled to announce that Recursion is setting a new gold standard for the industry with the release of ...
These are the 300 companies whose success goes beyond profits to include employee and customer sentiment, cybersecurity, ...
Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
Investor's Business Daily on MSN4d
Five S&P 500 Stocks, All Elite IBD Giants, Near Buy PointsMeta stock and Nvidia peer Broadcom are among among five S&P 500 stocks on IBD Leaderboard that are near buy points.
Investor's Business Daily on MSN4d
Dow Jones Surges On Trump, As Tesla, Palantir Fly; Five Stocks Still In RangeDow Jones futures will open Sunday evening, along with S&P 500 futures and Nasdaq futures, after stocks surged to record highs following Donald Trump's presidential victory.The Dow Jones and S&P 500 ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback